Refine
Year of publication
Language
- English (52)
Has Fulltext
- yes (52)
Is part of the Bibliography
- no (52)
Keywords
- immunotherapy (4)
- CIK cells (3)
- G-CSF (3)
- hematopoietic stem and progenitor cells (3)
- Apheresis (2)
- BMC (2)
- Bone defect (2)
- CAR (2)
- CXCL12 (2)
- CXCR4 (2)
- Cell therapy (2)
- Mobilization (2)
- Plerixafor (2)
- Stem cell (2)
- allogeneic stem cell transplantation (2)
- cell therapy (2)
- chimeric antigen receptor (2)
- cytokine-induced killer cells (2)
- hematopoiesis (2)
- hematopoietic stem cells (2)
- leukemia (2)
- rhabdomyosarcoma (2)
- stem cell transplantation (2)
- vaccination (2)
- AB-serum (1)
- AMD3100 (1)
- ASCT (1)
- Acute lymphoblastic leukemia (1)
- Allogeneic (1)
- Allogeneic stem cell transplantation (1)
- Anemia management (1)
- Blood loss calculator (1)
- Blood loss formula (1)
- Blood management (1)
- Bone marrow (1)
- Bone marrow mononuclear cells (1)
- Bone regeneration (1)
- CD19 (1)
- CD34 (1)
- CD34+ cell enumeration (1)
- CD34 + cells (1)
- CD49d (1)
- CHIP (1)
- Cancer chemotherapy (1)
- Cancer treatment (1)
- Cell binding (1)
- Cell differentiation (1)
- Cell processing (1)
- Cell-based therapies (1)
- CliniMACS (1)
- Clinical trial (1)
- DNA double-strand break repair (1)
- DSS /AOM (1)
- ERBB2 (1)
- ERBB2 (HER2/neu) (1)
- Engraftment (1)
- Epstein-Barr virus (1)
- Erythropoiesis (1)
- Ewing sarcoma (1)
- Filgrastim (1)
- Flow cytometry (1)
- Gene expression (1)
- Graft (1)
- Graft quality (1)
- HER2/neu (1)
- HSCT (1)
- Healthy stem cell donors (1)
- Hematopoietic stem cell (1)
- IL -17 (1)
- IL -23 (1)
- IL 23p19 knockout mouse (1)
- Immunosuppressive therapy (1)
- Immunotherapy (1)
- Integrins (1)
- Leukemias (1)
- Luciferase (1)
- MMF (1)
- MPA (1)
- MSC-subsets (1)
- MSM (1)
- Machine learning (1)
- Mesenchymal stromal cells (MSC) (1)
- Mouse models (1)
- Multiple sclerosis (1)
- NK-92 (1)
- NSG mice (1)
- Osteonecrosis (1)
- PEM-technology (1)
- Physical and mental health (1)
- Plasmacytoid dendritic cell (1)
- Post-thaw recovery (1)
- Proximal humeral fracture (1)
- Quality control (1)
- RBC (1)
- RBC-depletion (1)
- RMS (1)
- Regeneration (1)
- SARS-CoV-2 (1)
- SARS-CoV-2-specific T cells (1)
- SF-12 (1)
- Second donation (1)
- Sequence motif analysis (1)
- Stem cell dose (1)
- Stem cell enumeration (1)
- Stem cells (1)
- Surgical blood loss (1)
- Transcription factors (1)
- Transcriptional control (1)
- Transplant logistics (1)
- Transplantation (1)
- VLA4 (1)
- Volunteer donor (1)
- Wound healing potential (1)
- acute lymphoblastic leukemia (1)
- acute myeloid leukaemia (1)
- adoptive cancer immunotherapy (1)
- allogeneic (1)
- allogeneic donor (1)
- allogeneic hematological stem cell transplantation (1)
- antibiotic prophylactic therapy (1)
- autoimmune diabetes (1)
- autologous stem cell transplantation (1)
- automation (1)
- blood consumption (1)
- blood safety (1)
- bmal1 (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- breakpoint cluster region (1)
- cancer immunotherapy (1)
- cell motility (1)
- cellular therapy (1)
- charged particles (1)
- chemokine receptor 4 (1)
- chemotherapeutics-treated (1)
- chemotherapy (1)
- children (1)
- chromosomal breaks (1)
- chromosomal integration (1)
- chronic colitis (1)
- circadian rhythm (1)
- clean room (1)
- clock genes (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- colon cancer (1)
- cortisol (1)
- cryopreservation (1)
- cytotoxic T cells (1)
- donor deferral (1)
- donor recruitment (1)
- donor retention (1)
- donor safety (1)
- epigenetics (1)
- feeder cells (1)
- fresh frozen plasma (1)
- fully human (1)
- gene regulation (1)
- gene therapy (1)
- gene vectors (1)
- good manufacturing practice (1)
- graft-versus host (1)
- granulocytecolony stimulating factor (1)
- haplo-identical (1)
- hematopoietic stem cell mobilization (1)
- hematopoietic stem cell transplantation (1)
- hematopoietic stress (1)
- high-dose chemotherapy (1)
- hospital exemption (1)
- huCAR19 (1)
- immunomagnetic (1)
- induction chemotherapy (1)
- infection precaution (1)
- integrin (1)
- integrins (1)
- lymphoma (1)
- mesenchymal stromal cell (1)
- mobilization (1)
- naked haplo (1)
- natural cytotoxicity (1)
- natural killer cell (1)
- natural killer cells (1)
- nonviral gene delivery (1)
- oncogenes (1)
- p47phox (1)
- patient blood management (1)
- pharmacodynamics (1)
- platelet lysate (1)
- post-transplantation lymphoproliferative disease (1)
- preclinical (1)
- radiation damage response (1)
- radiation-induced leukemia (1)
- refractory aGvHD (1)
- serum albumin deficiency (1)
- sialitis (1)
- somatic mutations (1)
- steroid-resistant aGvHD (1)
- time-lapse imaging (1)
- transcription factors (1)
- transfusion (1)
- transgenically augmented CAR NK cell (1)
- transplantation (1)
- transposition (1)
- type-1-diabetes (1)
Institute
Background: The spontaneously diabetic “non-obese diabetic” (NOD) mouse is a faithful model of human type-1 diabetes (T1D). Methods: Given the pivotal role of α4 integrin (CD49d) in other autoimmune diseases, we generated NOD mice with α4-deficient hematopoiesis (NOD.α4-/-) to study the role of α4 integrin in T1D. Results: NOD.α4-/- mice developed islet-specific T-cells and antibodies, albeit quantitatively less than α4+ counterparts. Nevertheless, NOD.α4-/- mice were completely and life-long protected from diabetes and insulitis. Moreover, transplantation with isogeneic α4-/- bone marrow prevented progression to T1D of pre-diabetic NOD.α4+ mice despite significant pre-existing islet cell injury. Transfer of α4+/CD3+, but not α4+/CD4+ splenocytes from diabetic to NOD.α4-/- mice induced diabetes with short latency. Despite an only modest contribution of adoptively transferred α4+/CD3+ cells to peripheral blood, pancreas-infiltrating T-cells were exclusively graft derived, i.e., α4+. Microbiota of diabetes-resistant NOD.α4-/- and pre-diabetic NOD.α4+ mice were identical. Co- housed diabetic NOD.α4+ mice showed the characteristic diabetic dysbiosis, implying causality of diabetes for dysbiosis. Incidentally, NOD.α4-/- mice were protected from autoimmune sialitis. Conclusion: α4 is a potential target for primary or secondary prevention of T1D.
Mobilization of hematopoietic stem cells (HSCs) from the bone marrow to the peripheral blood is a complex mechanism that involves adhesive and chemotactic interactions of HSCs as well as their bone marrow microenvironment. In addition to a number of non-genetic factors, genetic susceptibilities also contribute to the mobilization outcome. Identification of genetic factors associated with HSC yield is important to better understand the mechanism behind HSC mobilization. In the present study, we enrolled 148 Korean participants (56 healthy donors and 92 patients) undergoing HSC mobilization for allogeneic or autologous HSC transplantation. Among a total of 53 polymorphisms in 33 candidate genes, one polymorphism (rs11264422) in relaxin/insulin-like family peptide receptor 4 (RXFP4) gene was significantly associated with a higher HSC yield after mobilization in Koreans. However, in a set of 101 Europeans, no association was found between circulating CD34+ cell counts and rs11264422 genotype. Therefore, we suggest that the ethnic differences in subjects’ genetic background may be related to HSC mobilization. In conclusion, the relaxin—relaxin receptor axis may play an important role in HSC mobilization. We believe that the results of the current study could provide new insights for therapies that use relaxin and HSC populations, as well as a better understanding of HSC regulation and mobilization at the molecular level.